Craig Crews

Craig Crews invented PROTAC (Proteolysis Targeting Chimera) technology at Yale University, creating the foundational concept of using bifunctional small molecules to recruit E3 ubiquitin ligases to disease-causing proteins for targeted degradation via the proteasome. His work transformed the drug discovery paradigm by enabling the pharmacological elimination of previously undruggable proteins including transcription factors and scaffolding proteins. He co-founded Arvinas, which developed ARV-471, the first oral PROTAC to demonstrate clinical efficacy in breast cancer.